MB
Matthew Biegler Oppenheimer Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
22
Avg Return
Past Year
Past Year
37%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past Year
Positive
100%
Neutral
0%
Negative
0%
Past Week
Past Month
Past 3 Months
Past 6 Months
Past Year
All Time
Positive
Neutral
Negative
Large Cap
$10B to $200B
Mid Cap
$2B to $10B
Small Cap
$250M to $2B
Micro Cap
Under $250M
Financials
Healthcare
Financials
Asset Management
Healthcare
Biotechnology
Drug Manufacturers - General
| Stock | Rating | Price Target |
Upside Downside |
Ratings 1 Year |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
|
Outperform
Maintained
| $50 |
74%
upside
| 1 | +20% |
0
%
| 3 Feb ‘26 3 months ago |
|
|
|
Outperform
Reiterated
| $865 |
43%
upside
| 1 | +2.2% |
0
%
| 2 Feb ‘26 4 months ago |
|
|
|
Outperform
Upgraded
| $14 |
11%
downside
| 1 | +39% |
0
%
| 26 Jan ‘26 4 months ago |
|
|
|
Outperform
Maintained
| $48 |
349%
upside
| 5 | +59% |
0
%
| 11 Dec ‘25 5 months ago |
|
|
|
Outperform
Initiated
| $45 |
144%
upside
| 1 | -19% |
0
%
| 4 Dec ‘25 6 months ago |
|
|
|
Outperform
Maintained
| $15 |
97%
upside
| 2 | +57% |
0
%
| 14 Nov ‘25 6 months ago |
|
|
|
Outperform
Maintained
| $22 |
166%
upside
| 2 | +0.48% |
0
%
| 13 Nov ‘25 6 months ago |
|
|
|
Outperform
Maintained
| $28 |
71%
upside
| 3 | +7.7% |
0
%
| 10 Oct ‘25 7 months ago |
|
|
|
Outperform
Maintained
| $8 |
410%
upside
| 3 | -3.1% |
0
%
| 14 Aug ‘25 9 months ago |
|
|
|
Outperform
Initiated
| $7 |
122%
upside
| 1 | +239% |
0
%
| 31 Jul ‘25 10 months ago |
|